Endogenous factor activating Na,K-ATPase induced by blockade of adrenoceptors. 1993

B N Manukhin, and P A Erokhov, and E V Volina
Institute of Developmental Biology, Russian Academy of Sciences, Moscow.

It was established that the regulatory factor released from the effector cells under the blockade of postsynaptic alpha- and beta-adrenoceptors by phentolamine and propranolol (0.5-1.0 microM) and activating noradrenergic uptake and synthesis increased the activity of Na,K-ATPase of isolated rat organs and partially purified Na,K-ATPase isolated from the rat brain. The regulatory factor is a protein with molecular mass 25-100 kDa, adsorbed on phenylsepharose CL-4B and eluated with 30 mM KCl. It consists of two active components with pI 5.1 and 5.9 which in admixture (1:1) activate Na,K-ATPase by 60%.

UI MeSH Term Description Entries
D007525 Isoelectric Focusing Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point. Electrofocusing,Focusing, Isoelectric
D008297 Male Males
D008560 Membrane Fluidity The motion of phospholipid molecules within the lipid bilayer, dependent on the classes of phospholipids present, their fatty acid composition and degree of unsaturation of the acyl chains, the cholesterol concentration, and temperature. Bilayer Fluidity,Bilayer Fluidities,Fluidities, Bilayer,Fluidities, Membrane,Fluidity, Bilayer,Fluidity, Membrane,Membrane Fluidities
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011199 Potentiometry Solution titration in which the end point is read from the electrode-potential variations with the concentrations of potential determining ions. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D000254 Sodium-Potassium-Exchanging ATPase An enzyme that catalyzes the active transport system of sodium and potassium ions across the cell wall. Sodium and potassium ions are closely coupled with membrane ATPase which undergoes phosphorylation and dephosphorylation, thereby providing energy for transport of these ions against concentration gradients. ATPase, Sodium, Potassium,Adenosinetriphosphatase, Sodium, Potassium,Na(+)-K(+)-Exchanging ATPase,Na(+)-K(+)-Transporting ATPase,Potassium Pump,Sodium Pump,Sodium, Potassium ATPase,Sodium, Potassium Adenosinetriphosphatase,Sodium-Potassium Pump,Adenosine Triphosphatase, Sodium, Potassium,Na(+) K(+)-Transporting ATPase,Sodium, Potassium Adenosine Triphosphatase,ATPase Sodium, Potassium,ATPase, Sodium-Potassium-Exchanging,Adenosinetriphosphatase Sodium, Potassium,Pump, Potassium,Pump, Sodium,Pump, Sodium-Potassium,Sodium Potassium Exchanging ATPase,Sodium Potassium Pump
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

B N Manukhin, and P A Erokhov, and E V Volina
February 1983, Biulleten' eksperimental'noi biologii i meditsiny,
B N Manukhin, and P A Erokhov, and E V Volina
June 1993, Neurochemical research,
B N Manukhin, and P A Erokhov, and E V Volina
January 1963, Kita Kanto igaku. Kitakanto medical journal,
B N Manukhin, and P A Erokhov, and E V Volina
April 1998, Prostaglandins & other lipid mediators,
B N Manukhin, and P A Erokhov, and E V Volina
March 1994, Neuroscience research,
B N Manukhin, and P A Erokhov, and E V Volina
June 1991, Microscopia electronica y biologia celular : organo oficial de las Sociedades Latinoamericana de Microscopia Electronica e Iberoamericana de Biologia Celular,
B N Manukhin, and P A Erokhov, and E V Volina
January 1998, Neurochemical research,
B N Manukhin, and P A Erokhov, and E V Volina
March 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
B N Manukhin, and P A Erokhov, and E V Volina
May 1994, FEBS letters,
B N Manukhin, and P A Erokhov, and E V Volina
January 1987, Klinische Wochenschrift,
Copied contents to your clipboard!